ArticleFrontiers in genetics2025
The value of quantitative fluorescence polymerase chain reaction for the products of conception in the era of copy number variation sequencing.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this research was to assess the effectiveness of copy number variation sequencing (CNV-Seq) and quantitative fluorescence polymerase chain reaction (QF-PCR) in detecting chromosomal abnormalities in products of conception of women and to evaluate the pros and cons of three different combined detection strategies, CNV-Seq and QF-PCR. Methods: Genetic testing was conducted on 701 samples using QF-PCR and CNV-Seq. The detection efficiency of the two methods for various chromosomal abnormalities was calculated. The relationships between maternal age, miscarriage gestational age, number of prior miscarriages, and conception method with fetal chromosomal abnormalities were assessed. The detection efficiency and cost of three different combined detection strategies were compared. Results: Maternal cell contamination was found in 2.57% of samples. The overall occurrence rate of various chromosomal abnormalities was as high as 67.20% (459/683). QF-PCR was effective in detecting maternal cell contamination, triploidy, and common aneuploidies but was not effective in detecting mosaicism. Advanced maternal age, abnormal pregnancy history, early abortion, and naturally conceived products of conception were more likely to detect aneuploidy but were unrelated to triploidy and CNVs. Conclusion: QF-PCR can effectively complement the limitations of CNV-Seq. Employing QF-PCR to rule out maternal cell contamination prior to performing CNV-Seq on all samples is the best detection strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.